Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
LAMP2 expression dictates azacytidine response and prognosis in MDS/AML.
Dubois A, Furstoss N, Calleja A, Zerhouni M, Cluzeau T, Savy C, Marchetti S, Hamouda MA, Boulakirba S, Orange F, Lacas-Gervais S, Karsenti JM, Mounier N, Tamburini J, Puissant A, Luciano F, Jacquel A, Auberger P, Robert G. Dubois A, et al. Among authors: luciano f. Leukemia. 2019 Jun;33(6):1501-1513. doi: 10.1038/s41375-018-0336-1. Epub 2019 Jan 3. Leukemia. 2019. Retraction in: Leukemia. 2020 Sep;34(9):2544. doi: 10.1038/s41375-020-0969-8 PMID: 30607021 Retracted.
BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients.
Cluzeau T, Robert G, Mounier N, Karsenti JM, Dufies M, Puissant A, Jacquel A, Renneville A, Preudhomme C, Cassuto JP, Raynaud S, Luciano F, Auberger P. Cluzeau T, et al. Among authors: luciano f. Oncotarget. 2012 Apr;3(4):490-501. doi: 10.18632/oncotarget.481. Oncotarget. 2012. PMID: 22577154 Free PMC article.
Retraction Note: LAMP2 expression dictates azacytidine response and prognosis in MDS/AML.
Dubois A, Furstoss N, Calleja A, Zerhouni M, Cluzeau T, Savy C, Marchetti S, Hamouda MA, Boulakirba S, Orange F, Lacas-Gervais S, Karsenti JM, Mounier N, Tamburini J, Puissant A, Luciano F, Jacquel A, Auberger P, Robert G. Dubois A, et al. Among authors: luciano f. Leukemia. 2020 Sep;34(9):2544. doi: 10.1038/s41375-020-0969-8. Leukemia. 2020. PMID: 32665699 Free PMC article.
Differentiation inducing factor 3 mediates its anti-leukemic effect through ROS-dependent DRP1-mediated mitochondrial fission and induction of caspase-independent cell death.
Dubois A, Ginet C, Furstoss N, Belaid A, Hamouda MA, El Manaa W, Cluzeau T, Marchetti S, Ricci JE, Jacquel A, Luciano F, Driowya M, Benhida R, Auberger P, Robert G. Dubois A, et al. Among authors: luciano f. Oncotarget. 2016 May 3;7(18):26120-36. doi: 10.18632/oncotarget.8319. Oncotarget. 2016. PMID: 27027430 Free PMC article.
BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia.
Vidal V, Robert G, Goursaud L, Durand L, Ginet C, Karsenti JM, Luciano F, Gastaud L, Garnier G, Braun T, Hirsch P, Raffoux E, Nloga AM, Padua RA, Dombret H, Rohrlich P, Ades L, Chomienne C, Auberger P, Fenaux P, Cluzeau T. Vidal V, et al. Among authors: luciano f. Oncotarget. 2017 Jul 18;8(29):47103-47109. doi: 10.18632/oncotarget.17482. Oncotarget. 2017. PMID: 28514758 Free PMC article.
164 results